Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma.

Simon FietzEric DiekmannLuka de VosRomina ZarblAlina HuneckeAnn-Kathrin GloschMoritz FärberJudith SirokayFriederike HoffmannAnne FröhlichAlina FranzenSebastian StriethJennifer LandsbergDimo Dietrich

Published in: Clinical chemistry (2024)

Our study suggests SHOX2 ccfDNAm to be an early predictor of outcome in anti-PD-1 treated melanoma patients. SHOX2 ccfDNAm testing may aid individualized treatment decision-making.

Keyphrases

cell free
dna methylation
newly diagnosed
end stage renal disease
decision making
ejection fraction
chronic kidney disease
early stage
peritoneal dialysis
genome wide
skin cancer
patient reported outcomes
copy number
basal cell carcinoma
patient reported